Oryzon Genomics S.A. Acciones Port. EO -,05
- BID
2.85
- ASK
2.852
- 375 Units375 Units
- 07/21, 21:59:02 PM
Sector and Industry
Healthcare, Biopharmaceuticals
Performance (1Y)
3.45%
Market Cap
-
P/E Ratio
0.00
Dividend Yield
0.00 %
Earnings per Share
-0.04 €
Peer Group
| Company Name | Market Cap | Revenue Last Reported Year | P/E Ratio | Profit Growth 1Y | Last Price | Previous Trading Day Change |
|---|---|---|---|---|---|---|
| Eli Lilly and Company | 864.54 Bil. | 57.78 Bil. | 46.82 | +86.88 % | 0.00 | - |
| Johnson & Johnson | 425.70 Bil. | 83.48 Bil. | 18.82 | +82.71 % | 0.00 | - |
| AbbVie Inc. | 343.94 Bil. | 54.21 Bil. | 96.78 | -5.29 % | 0.00 | - |
| Roche Holding AG | 286.62 Bil. | 65.80 Bil. | 20.72 | +58.45 % | 0.00 | - |
| AstraZeneca PLC | 244.91 Bil. | 52.09 Bil. | 27.55 | +39.41 % | 0.00 | - |
| NOVARTIS AG | 224.76 Bil. | 48.44 Bil. | 18.30 | +12.45 % | 0.00 | - |
| Merck & Co. Inc. | 221.79 Bil. | 57.55 Bil. | 14.46 | +2.25 % | 0.00 | - |
| Novo-Nordisk AS B | 193.52 Bil. | 41.49 Bil. | 14.11 | +1.54 % | 0.00 | - |
| Amgen Inc. | 150.16 Bil. | 32.57 Bil. | 23.01 | +80.77 % | 0.00 | - |
| Gilead Sciences Inc. | 129.70 Bil. | 26.10 Bil. | 18.10 | +1,599.93 % | 0.00 | - |
Facts & figures
Price data
| TRADE PLATFORM | Börse Stuttgart (XSTU) | |
| LAST PRICE | 2.85 G | 0 Units |
| PRICE DETERMINATION TIME | 07/21/2026 / 09:56:22 PM | |
| DAILY VOLUME (UNITS) | 0 | |
| DAILY HIGH / LOW | 2.852 | 2.81 |
| PREV. DAY'S PRICE | 2.814 | (07/20) |
| CHANGE DAY BEFORE | +0.04 | 1.28 % |
| 52 WEEK HIGH / LOW | 3.85 (10/10) | 2.525 (08/21) |
Key Figures (in EUR)
| 2023 | 2024 | 2025 | 2026e | 2027e | |
|---|---|---|---|---|---|
EARNINGS PER SHARE | -0.06 | -0.06 | -0.04 | -0.09 | -0.09 |
DIVIDENDS PER SHARE | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
DIVIDEND YIELD IN % | 0.00 % | 0.00 % | 0.00 % | - | - |
DIVIDEND GROWTH IN % | - | - | - | - | - |
PRICE - EARNINGS RATIO | - | - | - | - | - |
PRICE - BOOK RATIO | 1.53 | 1.13 | 2.29 | - | - |
PRICE - SALES RATIO | - | - | - | - | - |
PRICE - CASH FLOW RATIO | - | - | - | - | - |
Master Data
| WKN | A2ACV2 |
| ISIN | ES0167733015 |
| SYMBOL | ORN |
| EXCHANGE SEGMENT | Freiverkehr |
| TYPE OF FINANCIAL INSTRUMENT | Equity |
| DENOMINATION | ORYZON GENOMICS SA EO-,05 |
| INDEX MEMBERSHIP | - |
| TRADING SEGMENT | - |
| TRADING HOURS | 07:30:00 AM - 10:00:00 PM |
| TRADING CURRENCY | Euro |
| NOMINAL CURRENCY | - |
| SETTLEMENT CURRENCY | Euro |
| SECTOR AND INDUSTRY | Healthcare, Biopharmaceuticals |
| NUMBER OF SHARES | - |
| MARKET CAPITALISATION | - |
Performance overview
| 1W | 1M | 3M | 6M | 1Y | 3Y | 5Y | YTD | |
|---|---|---|---|---|---|---|---|---|
| PERFORMANCE | -0.97 % | -8.30 % | 1.71 % | -11.76 % | 3.45 % | 39.36 % | -18.22 % | -8.06 % |
| HIGH | 2.90 | 3.20 | 3.25 | 3.32 | 3.85 | 3.85 | 3.85 | 3.33 |
| LOW | 2.80 | 2.73 | 2.69 | 2.63 | 2.53 | 1.38 | 1.38 | 2.63 |
Dividende
pro Aktie
ORYZON GENOMICS SA EO-,05 does not deliver dividend information
Company profile
Oryzon Genomics SA is a clinical stage biopharmaceutical company, which engages in the discovery, research, and development of new chemical entities, as well as conducting clinical trials. It focuses on epigenetics in various therapeutic indications, with a special emphasis on oncology and neurodegenerative disease. The firm's product pipelines include Iadademstat and Vafidemstat. The company was founded by Carlos Manuel Buesa Arjol and Tamara Maes on June 2, 2000 and is headquartered in Barcelona, Spain.
Analyst Rating
Ø-Target Price DistanceNot Available
Current Price
Not AvailableØ-Target Price
Not AvailableAverage ResultNot Available
Buy0
Overweight0
Hold0
Underweight 0
Sell0
Company Events
No company events available.